What is the recommended praziquantel dosage for hepatic schistosomiasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Praziquantel Dosage for Hepatic Schistosomiasis

For hepatic schistosomiasis, administer praziquantel 40 mg/kg as a single oral dose for S. mansoni, S. intercalatum, and S. guineensis, or 60 mg/kg divided into two doses on the same day for S. japonicum and S. mekongi, with a mandatory repeat dose at 6-8 weeks regardless of species. 1

Species-Specific Dosing Algorithm

The dosing regimen depends entirely on identifying the infecting Schistosoma species:

For S. mansoni, S. haematobium, S. intercalatum, or S. guineensis:

  • 40 mg/kg as a single oral dose on day 1 2, 1
  • Repeat the identical 40 mg/kg dose at 6-8 weeks after initial treatment 2, 1
  • Always administer with food to optimize absorption 2

For S. japonicum or S. mekongi:

  • 60 mg/kg divided into two doses on the same day (e.g., 30 mg/kg twice, 4-6 hours apart) 2, 1
  • Repeat the identical 60 mg/kg divided-dose regimen at 6-8 weeks 1
  • Always administer with food 2

For serology-positive cases from Asia-Pacific region with uncertain species:

  • Use the higher 60 mg/kg divided-dose regimen to ensure adequate coverage 1

Why Repeat Dosing is Mandatory

The 6-8 week repeat dose is non-negotiable for all species because immature schistosomules are relatively resistant to praziquantel and survive the initial treatment. 2, 1 This is not optional—single-dose therapy alone is inadequate. 1

Dosing in Hepatic Impairment

Maintain the standard 40 mg/kg dose even in patients with liver cirrhosis or hepatic dysfunction—do not reduce the dose. 1 This recommendation may seem counterintuitive, but research demonstrates that despite altered pharmacokinetics in hepatic impairment (increased half-life, higher maximum concentration, and greater area under the curve), cure rates remain excellent at 90% in patients with advanced liver disease. 3 The increased drug exposure in cirrhotic patients does not translate to increased toxicity, and dose reduction would compromise efficacy. 3

Critical Drug Interactions to Avoid

Never use dexamethasone concurrently with praziquantel—it significantly reduces praziquantel serum levels through increased hepatic metabolism, leading to treatment failure. 2, 4 If corticosteroids are necessary (e.g., for acute Katayama syndrome or neuroschistosomiasis), use prednisolone 20-30 mg daily for 5 days instead. 2, 4

Monitoring Treatment Success

  • Do not use serology to assess treatment success—antibodies remain positive for years after successful parasite eradication. 2, 1
  • If viable eggs persist after completing both the initial and 6-8 week repeat dose, this indicates true treatment failure and requires specialist consultation. 1
  • Consider combination therapy with artemisinin derivatives in documented treatment failure, though clinical trial evidence is limited. 1

Expected Efficacy

Cure rates with the standard 40 mg/kg regimen are approximately 77% for S. haematobium, 77% for S. mansoni, and 95% for S. japonicum. 5 Cure rates of 70-76% after a single dose are normal and should not be misinterpreted as resistance—this is why the repeat dose at 6-8 weeks is essential. 2 Egg reduction rates exceed 86% for all species. 5

Common Side Effects

Approximately 57% of patients experience adverse events, most commonly abdominal pain (31%), dizziness, and diarrhea. 6, 5 These effects are transient and mild, even in patients with advanced hepatic dysfunction. 3 The incidence of side effects correlates with pre-treatment infection intensity. 6

Special Considerations for Hepatic Schistosomiasis

  • Screen for endemic coinfections (hepatitis B, hepatitis C, HIV, Salmonella species) before initiating therapy, as these modify disease severity. 1
  • Never use immunosuppressive medications in schistosomal hepatopathy—they provide no benefit and worsen outcomes. 1
  • Consider kidney biopsy in patients with schistosome-associated glomerulonephritis and viral coinfections to guide management. 1

References

Guideline

Treatment of Bilharzia (Schistosomiasis)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Praziquantel Treatment Guidelines for Schistosomiasis and Fluke Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Praziquantel and Progesterone Safety Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire.

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004

Related Questions

What is the appropriate praziquantel dose for hepatic schistosomiasis, including in patients with moderate to severe hepatic impairment and children older than 2 years?
What is the recommended dosing of praziquantel for the treatment of hepatic schistosomiasis?
What is the recommended dosing regimen for praziquantel in the treatment of schistosomiasis and other fluke infections?
Should Praziquantel be taken with food?
What is the recommended treatment and dosage of Praziquantel for pediatric patients with schistosomiasis or intestinal fluke infections?
When should serum potassium be rechecked after initiating or adjusting oral potassium supplementation (especially ≥40 mEq/day or in patients with renal impairment, diuretic use, myocardial disease, or recent severe hypokalaemia)?
In a patient on nivolumab (anti‑PD‑1) and ipilimumab (anti‑CTLA‑4) who now has thrombocytopenia (platelet count <75 ×10⁹/L), elevated liver enzymes (AST/ALT >5 × upper‑limit of normal or bilirubin >3 × ULN) and fatigue limiting daily activities, how should these immune‑related adverse events be graded and managed, including when to hold therapy, steroid dosing, and use of additional immunosuppression?
What are the possible causes and recommended work‑up for white frothy vomit in a newborn?
What is the recommended evaluation and management—including acute, preventive, and medication‑overuse strategies—for a patient with chronic headache occurring on 15 or more days per month for at least three months?
In a patient with right lower‑quadrant or groin pain, how should I evaluate for an incarcerated inguinal hernia versus acute appendicitis?
For a 43‑year‑old woman who completed metronidazole (Flagyl) for bacterial vaginosis and was asymptomatic, now presenting with isolated vaginal itching, should I do anything besides repeat a vaginal swab for microscopy, culture, and NAAT?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.